GlassScriptPhysician profile
Amy Goodwin Baird
NPI 1073697546
$7,107.75
in general payments reported to CMS, 2019-2025
42 companies · $1,544 in 2025
The $1,544 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,405 · 2022: $1,709 · 2023: $1,322 · 2024: $1,127 · 2025: $1,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,991 · Education: $2.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,991.30 |
| Education | $2.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,026.15 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $911.95 | 2021-2025 | Mounjaro, Trulicity, Humulin |
| Abbott Laboratories | $887.90 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Insulet Corporation | $587.65 | 2021-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.87 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Esperion Therapeutics, INC. | $312.80 | 2021-2025 | Nexletol |
| Tandem Diabetes Care, INC. | $289.75 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $216.82 | 2021-2025 | |
| Amgen INC. | $211.93 | 2021-2025 | Repatha, Tepezza, Repatha |
| Astrazeneca Pharmaceuticals LP | $193.42 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $192.93 | 2022-2025 | Isturisa |
| Xeris Pharmaceuticals, INC. | $187.37 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Medtronic, INC. | $161.51 | 2021-2025 | Minimed 780g, Minimed 770g, Intellis Adaptivestim |
| Mannkind Corporation | $152.25 | 2021-2022 | |
| Corcept Therapeutics | $148.13 | 2023-2025 | Korlym |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Baird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.